Company intelligence / Profile preview
Qingfeng Pharmaceutical Group
Ganzhou, Jiangxi, Chinaqfyy.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Qingfeng has several approved products in China and internationally—including recent US approvals for Eribulin Mesilate Injection and Enzalutamide API/capsules—and is advancing nearly 60 new molecular entities through its global pipeline. The group emphasizes innovation with both small molecules and herbal/natural medicines.
- Therapeutic areas
- GastroenterologyEndocrinologyOtherOncologyNeurologyInfectious Diseases
- Modalities
- Small molecule drugsHerbal medicinesChemical drugsProphylactic vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with Detective Xiang for laboratory infrastructureacademic/research collaborations domestically/internationally
Beyond the preview
Go deeper on Qingfeng Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingfeng Pharmaceutical Group.